Nautilus
Delivering a high-throughput, low-cost platform for analyzing and quantifying the human proteome.
Launch date
Employees
Market cap
€331m
Enterprise valuation
€208m (Public information from Sep 2024)
Share price
$2.87 NAUT
San Carlos California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | <1m | 10.6m | 34.2m |
| % growth | - | - | - | - | - | 5108 % | 221 % |
| EBITDA | (13.4m) | (47.7m) | (60.2m) | (70.4m) | (84.6m) | (97.8m) | (102m) |
| % EBITDA margin | - | - | - | - | (41390 %) | (919 %) | (300 %) |
| Profit | (15.6m) | (50.3m) | (57.9m) | (63.7m) | (82.9m) | (103m) | (109m) |
| % profit margin | - | - | - | - | (40592 %) | (968 %) | (319 %) |
| EV / revenue | - | - | - | - | 1339.7x | 25.0x | 6.2x |
| EV / EBITDA | - | -6.2x | -0.7x | -2.8x | -3.2x | -2.7x | -2.0x |
| R&D budget | 12.4m | 29.4m | 37.7m | 47.3m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $27.2m | Series A | |
* | $76.0m | Series B | |
$150m Valuation: $1.3b -97.0x EV/LTM EBITDA | SPAC IPO | ||
$200m Valuation: $1.3b -97.0x EV/LTM EBITDA | SPAC Private Placement | ||
| N/A | N/A | IPO | |
| Total Funding | €276m | ||
